As the Fed begins its two-day policy meeting Tuesday, markets will get a look at how consumers behaved just before the government shut down.» Read More
Take a look at some of Wednesday's midday movers:
Stocks exit April on a new high, and with the promise of continuing easy money policies, investors could be tempted to rethink the "sell in May and go away" strategy of recent years.
Get ready. Cramer sees the potential for problems around Wednesday.
Take a look at some of Tuesday's midday movers:
One contributor to TheStreet.com advises investors to do their own due diligence before investing in Allergan. From a technical basis it would not surprise him to see shares head closer to $100 before heading higher.
Are you working it? If you want to bend it like Jim Cramer you’d better be.
Allergan, the maker of the Botox anti-wrinkle treatment, said its Q4 earnings rose. Allergan CEODavid Pyott talks with Mad Money host Jim Cramer.
This is one of my absolute favorite growth pharma names, said Cramer.
CNBC's Seema Mody reports on some big movers at the Nasdaq.
According to Cramer a shift is underway. You’d best position for it now.
Oct 12- Watson Pharmaceuticals Inc:. *Watson's generic sanctura xrï¿ ½ receives FDA approval. *Says intends to begin shipping the product immediately.
*Nomura cuts Aegon to neutral from buy For a summary of rating actions and price target changes on European companies:. Reuters Eikon users, click on. Reuters Station users, click. 1580.
--We based our opinion of AEGON's primary servicing operation on the company's long, successful track record servicing multifamily/commercial real estate loans primarily originated for life insurance companies, experienced management team, good leverage of technology, and sound control environment.
*Comments on order regarding permanent injunction against Merz Pharmaceuticals. *Order restricts Merz Pharmaceuticals' ability to sell& solicit purchases of. Xeomin to remain in place until November 1,2012.
--We have reviewed Saecure 8 NHG and Saecure 9 as part of our surveillance review cycle. --Arrears levels are low and the level of credit enhancement has increased for all classes of notes in both transactions, due to deleveraging. Standard& Poor's Ratings Services today affirmed its credit ratings on all classes notes in Saecure 8 NHG B.V. and Saecure 9 B.V..
David Pyott, Allergan president and CEO discusses his company's 2012 outlook and the Botox market.
Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.
Allergan filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladders. David Pyott, chairman & CEO of Allergan, offers insight on Botox and its many uses.
David Pyott, Allergan chairman/CEO, discusses the company's earnings, and products in the big pharma pipeline, with Mad Money's Jim Cramer.
Allergan is finding ways to deliver returns for investors in a struggling market and discussing business strategies behind the brand, with David Pyott, Allergan chairman/CEO.